Thomas J. Spillane
Expertise in
74
conditions

Dr. Thomas J. Spillane

Oncology
CommonSpirit Health
Cancer Center - Dignity Health - San Luis Obispo, CA
715 Tank Farm Rd, Suite C, 
San Luis Obispo, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
74
conditions
CommonSpirit Health
Cancer Center - Dignity Health - San Luis Obispo, CA
715 Tank Farm Rd, Suite C, 
San Luis Obispo, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Dr. Tom Spillane believes in an integrative approach to the management of his patients. His definition of an integrative approach combines the best of the updated western medicine technology, complementary care, clinical trials and local psychosocial support services.Dr. Spillane co-founded the Hearst Cancer Resource Center in 2008, as well as the Surfing for Hope Foundation  in 2011, a program that among other services takes cancer survivors and children whose parents are battling cancer, on monthly surf sessions.Board Certification:Oncology, HematologyMedical School:University of California, DavisMedical Oncology Residency:University of California, IrvineFellowship Training:University of California, IrvineAreas of Interest:Brain tumors, Breast Cancer, GI Cancers, Head and Neck Cancer, Lung Cancer, Melanoma.

Dr. Spillane is highly rated in 74 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Lynch Syndrome.

His clinical research consists of participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of California Davis
Residency
University of California, Irvine
Specialties
Oncology
Licenses
Internal Medicine in CA
Board Certifications
Internal Medicine (Sub: Medical Oncology)
Fellowships
University of California, Irvine
Hospital Affiliations
Arroyo Grande Community Hospital
French Hospital Medical Center
Marian Regional Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Moda Health
  • EPO
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Cancer Center - Dignity Health - San Luis Obispo, CA
715 Tank Farm Rd, Suite C, San Luis Obispo, CA 93401
Call: 805-543-5577

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: July 03, 2024
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Study Phase: Phase 3
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
An Observational Study to Collect and Assess Tissue Samples From Subjects With One of Three Neoplastic Conditions (ANSWer)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Other
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 10 Less Clinical Trials
Similar Doctors
Expertise in
46
conditions
Dr. Brian A. Dicarlo
Oncology
Expertise in
46
conditions
Dr. Brian A. Dicarlo
Oncology

UCLA Health Hematology Oncology

892 Aerovista Pl, Ste 240, 
San Luis Obispo, CA 
 (21.9 miles away)
805-541-8252
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Dicarlo is an Oncologist in San Luis Obispo, California. Dr. Dicarlo is highly rated in 46 conditions, according to our data. His top areas of expertise are Familial Pancreatic Cancer, Paget Disease of the Breast, Lung Cancer, and Large-Cell Immunoblastic Lymphoma. Dr. Dicarlo is currently accepting new patients.

Expertise in
16
conditions
Dr. Gregory M. Heestand
Oncology | Hematology Oncology | Hematology
Expertise in
16
conditions
Dr. Gregory M. Heestand
Oncology | Hematology Oncology | Hematology

Stanford Health Care

1310 Las Tablas Rd, Suite 204, 
Templeton, CA 
 (0.3 miles away)
805-434-3458
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Gregory Heestand is an Oncologist and a Hematologist Oncology provider in Templeton, California. Dr. Heestand is highly rated in 16 conditions, according to our data. His top areas of expertise are Fibrolamellar Carcinoma, Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Pancreatic Cancer, and Tissue Biopsy.

Lin Soe
Expertise in
52
conditions
Dr. Lin Soe
Oncology | Internal Medicine
Expertise in
52
conditions
Dr. Lin Soe
Oncology | Internal Medicine

Cancer Center - Dignity Health - San Luis Obispo, CA

715 Tank Farm Rd, Suite C, 
San Luis Obispo, CA 
 (21.6 miles away)
805-543-5577
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Board Certification:Oncology & HematologyFellowship Training:Oncology & Hematology from University California DavisInternal Medicine Residency:Cornell UniversityMedical School:Institute of Medicine I, Ragoon, BurmaEducation:Masters of Public Health and Tropical Medicine Tulane UniversityAreas of Interest: Benign Hematology, Breast Cancer, Gastrointestinal Malignancies, Lung Cancer, Solid Tumors. Dr. Soe is highly rated in 52 conditions, according to our data. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Myelodysplastic Syndrome (MDS), and Pleuropulmonary Blastoma.

VIEW MORE Oncologists

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spillane's expertise for a condition
ConditionClose
    • Distinguished
    • Anal Cancer
      Dr. Spillane is
      Distinguished
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Breast Cancer
      Dr. Spillane is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Spillane is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Spillane is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Spillane is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Lung Adenocarcinoma
      Dr. Spillane is
      Distinguished
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    View All 15 Distinguished Conditions
    • Advanced
    • Adult Immune Thrombocytopenia
      Dr. Spillane is
      Advanced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Agranulocytosis
      Dr. Spillane is
      Advanced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Spillane is
      Advanced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Ampullary Cancer
      Dr. Spillane is
      Advanced
      . Learn about Ampullary Cancer.
      See more Ampullary Cancer experts
    • Angiosarcoma
      Dr. Spillane is
      Advanced
      . Learn about Angiosarcoma.
      See more Angiosarcoma experts
    • Atypical Teratoid Rhabdoid Tumor (ATRT)
      Dr. Spillane is
      Advanced
      . Learn about Atypical Teratoid Rhabdoid Tumor (ATRT).
      See more Atypical Teratoid Rhabdoid Tumor (ATRT) experts
    View All 59 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Spillane is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Acute Lymphoblastic Leukemia (ALL)
      Dr. Spillane is
      Experienced
      . Learn about Acute Lymphoblastic Leukemia (ALL).
      See more Acute Lymphoblastic Leukemia (ALL) experts
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Spillane is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Spillane is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Spillane is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Adenoid Cystic Carcinoma
      Dr. Spillane is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    View All 110 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    1. Homepage
    2. Oncologists San Luis Obispo, CA
    3. Dr. Thomas J. Spillane
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.